4.4 Article

Cell Purification: A New Challenge for Biobanks

Journal

PATHOBIOLOGY
Volume 81, Issue 5-6, Pages 261-275

Publisher

KARGER
DOI: 10.1159/000358306

Keywords

Biobanks; High-throughput cell sorting; Pure cells; Fluorescence-activated cell sorting; Magnetic-activated cell sorting; High-quality sample collections

Funding

  1. Instituto de Salud Carlos III of the Ministry of Economy and Competitiveness of Spain: Plataforma de Recursos Biomoleculares y Bioinformaticos [PT13/0001/0037]
  2. Plataforma de Biobancos [PT13/0010/0067]

Ask authors/readers for more resources

Performing '-omics' analyses on heterogeneous biological tissue samples, such as blood or bone marrow, can lead to biased or even erroneous results, particularly when the targeted cells and/or molecules are present at relatively low percentages/amounts. In such cases, whole sample analysis will most probably dilute and mask the features of the cell and/or molecules of interest, and this will negatively impact the results and their interpretation. Therefore, frequently it is critically important to have well-characterized and high-quality purified cell populations for the reliable detection of subtle variations in their specific features, such as gene expression profile, protein expression pattern and metabolic status. Biobanks are technological platforms which aim to provide researchers access to a large number of high-quality biological samples and their associated data, particularly to support high-quality scientific and clinical research projects, and such projects will benefit enormously by having access to high-quality purified cell populations or their biological components (e.g. DNA, RNA, proteins). Therefore, a clear opportunity exists for preparative cell sorting techniques in biobanks. Although multiple different cell purification approaches exist or are under development (e.g. cell purification techniques based on cell adherence, density and/or cell size properties, methods based on antibody binding as well as new lab-on-a-chip purification techniques), the choice for a specific technology depends on multiple variables, including cell recovery, purity and yield, among others. In addition, most cell purification approaches are not well suited for high-throughput (HT) purification of multiple cell populations coexisting in a sample. Here we review the most (currently) used cell sorting methods that may be applied for sample preparation in biobanks. For the different approaches, technical considerations about their advantages and limitations are highlighted, and the requirements to be met by a HT cell sorting technology to be used in biobanks are also discussed. (C) 2015 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression

Andres C. Garcia-Montero, Maria Jara-Acevedo, Ivan Alvarez-Twose, Cristina Teodosio, Laura Sanchez-Munoz, Carmen Muniz, Javier I. Munoz-Gonzalez, Andrea Mayado, Almudena Matito, Carolina Caldas, Jose M. Morgado, Luis Escribano, Alberto Orfao

BLOOD (2016)

Article Hematology

Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients

Laura Sanchez-Munoz, Jose M. Morgado, Ivan Alvarez-Twose, Almudena Matito, Andres C. Garcia-Montero, Cristina Teodosio, Maria Jara-Acevedo, Andrea Mayado, Manuela Mollejo, Carolina Caldas, David Gonzalez de Olano, Luis Escribano, Alberto Orfao

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Article Allergy

Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis

Ivan Alvarez-Twose, Maria Jara-Acevedo, Jose Mario Morgado, Andres Garcia-Montero, Laura Sanchez-Munoz, Cristina Teodosio, Almudena Matito, Andrea Mayado, Carolina Caldas, Manuela Mollejo, Alberto Orfao, Luis Escribano

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)

Article Dermatology

Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

Adria Aterido, Antonio Julia, Carlos Ferrandiz, Lluis Puig, Eduardo Fonseca, Emilia Fernandez-Lopez, Esteban Dauden, Jose Luis Sanchez-Carazo, Jose Luis Lopez-Estebaranz, David Moreno-Ramirez, Francisco Vanaclocha, Enrique Herrera, Pablo de la Cueva, Nick Dand, Nuria Palau, Arnald Alonso, Maria Lopez-Lasanta, Rauel Tortosa, Andres Garcia-Montero, Laia Codo, Josep Lluis Gelpi, Jaume Bertranpetit, Devin Absher, Francesca Capon, Richard M. Myers, Jonathan N. Barker, Sara Marsal

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)

Letter Oncology

Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

I. Alvarez-Twose, P. Martinez-Barranco, J. Gotlib, A. Garcia-Montero, J. M. Morgado, M. Jara-Acevedo, J. D. Merker, F. J. Penalver, A. Matito, Y. Hou, L. Sanchez-Munoz, A. Mayado, M. Mollejo, L. Escribano, A. Orfao

LEUKEMIA (2016)

Article Rheumatology

A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis

Antonio Julia, Isidoro Gonzalez, Antonio Fernandez-Nebro, Francisco Blanco, Luis Rodriguez, Antonio Gonzalez, Juan D. Canete, Joan Maymo, Mercedes Alperi-Lopez, Alejandro Olive, Hector Corominas, Victor Martinez-Taboada, Alba Erra, Simon Sanchez-Fernandez, Arnald Alonso, Maria Lopez-Lasanta, Raul Tortosa, Laia Codo, Josep Lluis Gelpi, Andres C. Garcia-Montero, Jaume Bertranpetit, Devin Absher, S. Louis Bridges, Richard M. Myers, Jesus Tornero, Sara Marsal

RHEUMATOLOGY (2016)

Review Oncology

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature

Ivan Alvarez-Twose, Almudena Matito, Jose Mario Morgado, Laura Sanchez-Munoz, Maria Jara-Acevedo, Andres Garcia-Montero, Andrea Mayado, Carolina Caldas, Cristina Teodosio, Javier Ignacio Munoz-Gonzalez, Manuela Mollejo, Luis Escribano, Alberto Orfao

ONCOTARGET (2017)

Article Rheumatology

Identification of IRX1 as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study

Antonio Julia, Francisco Blanco, Benjamin Fernandez-Gutierrez, Antonio Gonzalez, Juan D. Canete, Joan Maymo, Mercedes Alperi-Lopez, Alex Olive, Hector Corominas, Victor Martinez-Taboada, Isidoro Gonzalez-Alvaro, Antonio Fernandez-Nebro, Alba Erra, Simon Sanchez-Fernandez, Arnald Alonso, Maria Lopez-Lasanta, Raul Tortosa, Laia Codo, Josep Lluis Gelpi, Andres C. Garcia-Montero, Jaume Bertranpetit, Devin Absher, Richard M. Myers, Jesus Tornero, Sara Marsal

ARTHRITIS & RHEUMATOLOGY (2016)

Article Genetics & Heredity

Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis

Gabriella Galata, Andres C. Garcia-Montero, Thomas Kristensen, Ahmed A. Z. Dawoud, Javier Munoz-Gonzalez, Manja Meggendorfer, Paola Guglielmelli, Yvette Hoade, Ivan Alvarez-Twose, Christian Gieger, Konstantin Strauch, Luigi Ferrucci, Toshiko Tanaka, Stefania Bandinelli, Theresia M. Schnurr, Torsten Haferlach, Sigurd Broesby-Olsen, Hanne Vestergaard, Michael Boe Moller, Carsten Bindslev-Jensen, Alessandro M. Vannucchi, Alberto Orfao, Deepti Radia, Andreas Reiter, Andrew J. Chase, Nicholas C. P. Cross, William J. Tapper

Summary: Three intergenic SNPs associated with mastocytosis were identified, with one SNP showing association with age at presentation. These findings suggest that multiple germline variants predispose to KIT D816V positive mastocytosis and provide novel avenues for functional investigation.

AMERICAN JOURNAL OF HUMAN GENETICS (2021)

Article Hematology

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study

Javier Munoz-Gonzalez, Ivan Alvarez-Twose, Maria Jara-Acevedo, Roberta Zanotti, Cecelia Perkins, Mohamad Jawhar, Wolfgang R. Sperr, Khalid Shoumariyeh, Juliana Schwaab, Georg Greiner, Ana Henriques, Carolina Caldas, Carlos Fernandez-Gimenez, Laura Sanchez-Munoz, Andrea Mayado, Alba Perez-Pons, Annette Schmitt-Graeff, Justus Duyster, Ilaria Tanasi, Francesco Olivieri, Elvira Mora-Castera, Irene Luna, Leonor Senent, Maria-Helena Banas, Amanda Nunez-Garcia, Manuel Jurado-Chacon, Guillermo Martin-Sanchez, Enrique Colado, Blanca Xicoy, Georgina Gener-Ricos, Jason Gotlib, Patrizia Bonadonna, Andreas Reiter, Peter Valent, Andres C. Garcia-Montero, Alberto Orfao

Summary: A risk stratification model for systemic mastocytosis was designed and validated, showing clear discrimination between low-risk and high-risk patients for progression-free survival (PFS) and overall survival (OS) outcomes. The model was based on unique combinations of independent prognostic factors and showed high accuracy in predicting PFS and OS in both non-advanced and advanced systemic mastocytosis.

LANCET HAEMATOLOGY (2021)

Article Hematology

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

Ana Henriques, Javier Munoz-Gonzalez, Laura Sanchez-Munoz, Almudena Matito, Lidia Torres-Rivera, Maria Jara-Acevedo, Carolina Caldas, Andrea Mayado, Alba Perez-Pons, Andres C. Garcia-Montero, Ivan Alvarez-Twose, Alberto Orfao

Summary: This study used highly sensitive flow cytometry to detect the presence of circulating tumor mast cells (CTMCs) in various types of systemic mastocytosis (SM) patients. CTMCs were found in higher counts in advanced SM and smoldering SM patients, but in lower counts in indolent SM and bone marrow mastocytosis patients. The presence of CTMCs was associated with adverse features, prognostic scores, and survival in SM patients.

BLOOD (2022)

Review Oncology

Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

Oscar Gonzalez-Lopez, Javier I. Munoz-Gonzalez, Alberto Orfao, Ivan Alvarez-Twose, Andres C. Garcia-Montero

Summary: Systemic mastocytosis (SM) is a rare clonal hematopoietic stem cell disease characterized by the expansion and accumulation of neoplastic mast cells carrying the activating KIT D816V mutation. Assessment of multilineage involvement of hematopoiesis by KIT D816V and additional mutations in genes known to be associated with the prognosis of SM can help identify high-risk patients who may benefit from closer monitoring and early treatment. Mutations in multiple genes, including ASXL1, CBL, DNMT3A, EZH2, NRAS, RUNX1, and SRSF2, have been found to be associated with poorer outcomes in SM patients.

CANCERS (2022)

Article Allergy

Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

David Gonzalez-de-Olano, Paula Navarro-Navarro, Javier I. Munoz-Gonzalez, Laura Sanchez-Munoz, Ana Henriques, Ana de-Andres-Martin, Dolores Peralta-Arjonilla, Andrea Mayado, Maria Jara-Acevedo, Andres C. Garcia-Montero, Alberto Orfao, Ivan Alvarez-Twose

Summary: This study aimed to determine the prevalence of hereditary alpha-tryptasemia (HAT) in healthy donors vs patients with different diagnostic subtypes of mast cell (MC) activation syndromes (MCAS) and mastocytosis, and its relationship with the clinical behavior of the disease.

ALLERGY (2023)

Meeting Abstract Hematology

CHARACTERIZATION OF CD34+HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE

A. Mayado, C. Teodosio, N. Dasilva-Freire, M. Jara-Acevedo, A. Garcia-Montero, I. Alvarez-Twose, L. Sanchez-Munoz, A. Matito, C. Caldas, J. Munoz-Gonzalez, A. Henriques, J. Sanchez-Gallego, L. Escribano, A. Orfao

HAEMATOLOGICA (2017)

Meeting Abstract Hematology

CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE

C. Fernandez, C. Teodosio, S. Matarraz, A. Lopez, M. Jara-Acevedo, A. Mayado, I. Alvarez-Twose, L. Sanchez-Munoz, A. Garcia-Montero, M. L. Gutierrez, L. Escribano, A. Orfao

HAEMATOLOGICA (2016)

No Data Available